

External Quality Assessment Program for

Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Labquality EQAS by Aurevia is introducing a new EQA scheme “Bacterial vaginosis and vaginitis multiplex, nucleic acid detection” by arranging a pilot study free of charge for a limited number of participants. The scheme is intended for clinical laboratories diagnosing bacterial vaginosis based on the detection of specific bacterial nucleic acids (*Gardnerella vaginalis*, *Atopobium vaginae*, BVAB2, *Megasphaera* 2, and *Lactobacillus* spp.). Detection of *Candida* and *Trichomonas vaginalis* are also included in the scheme.

The pilot round includes three swab samples that should be analysed as regular patient samples. Participants submit their results via the electronic platform LabScala, and the results are processed by the EQA Coordinator.

5305 Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

Samples: 3 simulated swab samples

Distribution: March 2025

Registration: Please register by [this link](#) or by scanning this QR code no later than 17 February 2025



For more information

Aurevia's customer service info@aurevia.com or

Kati Luiro
EQA Coordinator
kati.luiro@aurevia.com
+358 40 661 4774

Heidi Berghäll
EQA Solutions manager, R&D
heidi.berghall@aurevia.com
+358 50 356 0503